Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized study of BXCL701 and pembrolizumab versus BXCL701 alone for treatment of small cell neuroendocrine prostate cancer

Next Previous
Trial Profile

A randomized study of BXCL701 and pembrolizumab versus BXCL701 alone for treatment of small cell neuroendocrine prostate cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Talabostat (Primary)
  • Indications Neuroendocrine carcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 12 Feb 2024 According to a BioXcel Therapeutics media release, the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of BXCL701 in combination with a CPI for the treatment of patients with metastatic small cell neuroendocrine prostate cancer (SCNC) with progression on chemotherapy and no evidence of microsatellite instability
  • 10 Oct 2023 According to a BioXcel Therapeutics media release, BioXcel Therapeutics will host a conference call and webcast on October 10, 2023 at 8:00 a.m.
  • 10 Oct 2023 According to a BioXcel Therapeutics media release, company announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the Company's investigational oral innate immune activator, in combination with KEYTRUDA (pembrolizumab) in patients with small cell neuroendocrine prostate cancer SCNC.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top